A phase 2 trial of Gremubamab compared to placebo in participants with bronchiectasis and chronic Pseudomonas aeruginosa infection

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2022-502494-41-00

Acronym

1-023-22

Enrollment

Registered

2023-09-19

Start date

2023-11-21

Completion date

2024-07-09

Last updated

2024-08-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

bronchiectasis and chronic Pseudomonas aeruginosa infection

Brief summary

Day 84

Detailed description

From Baseline to; Days 7, 14, 28 and 56, From Baseline to; Day 168, From Baseline to; Days 84 and 168, From Baseline to; Days 28, 56, 84 and 168, From Baseline to; First event from visit 1 to day 84, From Baseline to; Day 28, 56 and 84, From Baseline to; Over 168 days, From Baseline to; Over 168 days

Interventions

DRUGMEDI3902 PBO 4mL 10R

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Day 84	—

Secondary

Measure	Time frame
From Baseline to; Days 7, 14, 28 and 56, From Baseline to; Day 168, From Baseline to; Days 84 and 168, From Baseline to; Days 28, 56, 84 and 168, From Baseline to; First event from visit 1 to day 84, From Baseline to; Day 28, 56 and 84, From Baseline to; Over 168 days, From Baseline to; Over 168 days	—

Countries

Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026